Energy requirements of contraction and relaxation: implications for inotropic stimulation of the failing heart

  • Arnold M. Katz
Conference paper

Summary

It is likely that the myocardium in the patient with congestive heart failure is unable to provide enough chemical energy to meet its mechanical requirements. If this interpretation is correct, inotropic stimulation, by increasing energy utilization, could contribute to the progressive myocardial cell death that characterizes end-stage cardiac hypertrophy. This deterioration could be delayed by the depressed myocardial contractility in the chronically overloaded heart, which reduces myocardial energy utilization, and delayed by changes in the expression of myosin isoforms that improve cardiac efficiency. An important goal of therapy in congestive heart failure, therefore, may be to reduce energy expenditure by unloading the failing heart and, in some cases, by administration of negative inotropic drugs.

Keywords

Congestive Heart Failure Sarcoplasmic Reticulum Myosin Heavy Chain Gestive Heart Failure Myosin ATPase Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alpert NR, Gordon MS (1962) Myofibrillar adenosine triphosphatase activity in congestive heart failure. Am J Physiol 202: 940–946PubMedGoogle Scholar
  2. 2.
    Anversa P, Olivetti G, Melissari M, Loud AV (1980) Stereological measurement of cellular and subcellular hypertrophy and hyperplasia in the papillary muscle of adult rat. J Mol Cell Cardiol 12: 781–795PubMedCrossRefGoogle Scholar
  3. 3.
    Bashore TM, Magorien DJ, Letterio J, Shaffer P, Unverferth DV (1987) Histologic and biochemical correlates of left ventricular chamber dynamics in man. JACC 9: 734–742PubMedGoogle Scholar
  4. 4.
    Breitbart RE, Andreadis A, Nadal-Ginard B (1987) Alternative splicing: a ubiquitous mechanism for the generation of multiple protein isoforms from single genes. Ann Rev Biochem 56: 467–495PubMedCrossRefGoogle Scholar
  5. 5.
    Bugaisky L, Zak R (1986) Biological mechanisms of hypertrophy. In: Fozzard H, Haber E, Katz A, Jennings R, Morgan HE (eds) The heart and cardiovascular system. Raven Press, New York, pp 1491–1506Google Scholar
  6. 6.
    Charlemagne D, Maixen J-M, Preteseille M, Lelievre LG (1986) Ouabain binding sites and (Nat, K+)-ATPase activity in rat cardiac hypertrophy: expression of neonatal forms. J Biol Chem 261: 185–189PubMedGoogle Scholar
  7. 7.
    Cohn JN, Archibald DG, Ziesche S et al. (1986) Effect of vasodilator therapy on mortality on chronic congestive heart failure. Results of a Veterans Administration cooperative study ( VHeFT ). New Eng J Med 314: 1547–1552Google Scholar
  8. 8.
    CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Eng J Med 316: 1429–1435Google Scholar
  9. 9.
    Emerson CP Jr, Berstein SI (1987) Molecular genetics of myosin. Ann Rev Biochem 56: 695726Google Scholar
  10. 10.
    Furchgott RF, Lee KS (1961) High energy phosphates and the force of contraction of cardiac muscle. Circulation 24: 416–428PubMedCrossRefGoogle Scholar
  11. 11.
    Grossman W, Lorell B (1988) “Diastolic Relaxation of the Heart.” Martinus Nijoff Pub, BostonGoogle Scholar
  12. 12.
    Hamrell BB, Alpert NR (1986) Cellular basis of the mechanical properties of hypertrophied myocardium. In: Fozzard H, Haber E, Katz A, Jennings R, Morgan HE (eds) The heart and cardiovascular system. Raven Press, New York, pp 1507–1524Google Scholar
  13. 13.
    Harris P (1983) Evolution and the cardiac patient. Cardiovasc Res 17:313–319, 373–378, 437445CrossRefGoogle Scholar
  14. 14.
    Ingwall JS, Kramer MF, Fifer MA, Lorell BH, Shemin R, Grossman W, Allen PD (1985) The creatine kinase system in normal and diseased human myocardium. New Eng J Med 313: 10501054Google Scholar
  15. 15.
    Izumo S, Lompre A-M, Matsuoka R, Koren G, Schwartz K, Nadal-Ginard B, Mandavi V (1987) Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. J Clin Invest 79: 970–977PubMedCrossRefGoogle Scholar
  16. 16.
    Katz AM (1970) Contractile proteins of the heart. Physiol Rev 50: 58–163Google Scholar
  17. 17.
    Katz AM (1973) Biochemical “defect” in the hypertrophied and failing heart. Deleterious or compensatory? Circ 47: 1076–1079CrossRefGoogle Scholar
  18. 18.
    Katz AM (1976) Tonic and phasic mechanisms in the regulation of myocardial contractility. Basic Res Cardiol 71: 447–455, 1976Google Scholar
  19. 19.
    Katz AM (1978) A new inotropic drug: its promise and a caution. N Eng J Med 299: 1409–1410CrossRefGoogle Scholar
  20. 20.
    Katz AM (1984) Calcium fluxes across the sarcoplasmic reticulum. In: Opie LH (ed) Calcium antagonists and cardiovascular disease. Persp Cardiovasc Res 9: 53–66Google Scholar
  21. 21.
    Katz AM (1986) Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circ 73 (Suppl III):III-184—III-188Google Scholar
  22. 22.
    Katz AM (1988) Cellular mechanisms in congestive heart failure. Am J Cardiol (in press)Google Scholar
  23. 23.
    Litten RZ, Martin BJ, Low RB, Alpert NR (1982) Altered myosin isozyme pattern from pressure-overloaded and thyrotoxic hypertrophied rabbit hearts. Circ Res 50: 856–864PubMedCrossRefGoogle Scholar
  24. 24.
    Lompre AM, Schwartz K, D’Albis A, Lacombe G, Van Thiem N, Swynghedauw B (1975) Myosin isoenzyme redistribution in chronic heart overload. Nature 282: 105–107CrossRefGoogle Scholar
  25. 25.
    Meerson FZ (1961) On the mechanism of compensatory hyperfunction and insufficiency of the heart. Cor et Vasa 3: 161–177PubMedGoogle Scholar
  26. 26.
    Meerson FZ (1969) The myocardium in hyperfunction, hypertrophy and heart failure. Circ Res 25 (Suppl II):II-1—II-163Google Scholar
  27. 27.
    Meerson FZ, Javick MP (1982) Isozyme pattern and activity of myocardial creatine phosphokinase under heart adaptation to chronic overload. Basic Res Cardiol 77: 349–358PubMedCrossRefGoogle Scholar
  28. 28.
    Mercadier JJ, DeLaBastoe D, Menasche P, N’Guyen Van Cao A, Bouveret P, Lorente P, Piwnica A, Slama R, Schwartz K (1987) Alpha-myosin heavy chain isoform and atrial size in patients with various types of mitral valve dysfunction: a quantitative study. JACC 9: 10241030Google Scholar
  29. 29.
    Osler W (1892) The principles and practice of medicine. Appleton & Co, p 634Google Scholar
  30. 30.
    Page E, McCalister LP (1973) Quantitative electron microscopic description of heart muscle cells. Application to normal, hypertrophied and thyroxin-stimulated hearts. Am J Cardiol 31: 172–181Google Scholar
  31. 31.
    Penpargkul S, Repke DI, Katz AM, Scheuer J, Effect of physical training on calcium transport by rat cardiac sarcoplasmic reticulum. Circ Res 40: 134–138, 1977PubMedCrossRefGoogle Scholar
  32. 32.
    Pool PE, Spann JF, Buccino RA, Sonnenblick EH, Braunwald E (1967) Myocardial high energy phosphate stores in cardiac hypertrophy and heart failure. Circ Res 21: 365–373CrossRefGoogle Scholar
  33. 33.
    Rabinowitz M (1973) Protein synthesis and turnover in normal and hypertrophied heart. Am J Cardiol 31: 202–210PubMedCrossRefGoogle Scholar
  34. 34.
    Rupp H (1981) The adaptive changes in the isoenzyme pattern of myosin from hypertrophied rat myocardium as a result of pressure overload and physical training. Basic Res Cardiol 76: 79–88PubMedCrossRefGoogle Scholar
  35. 35.
    Scheuer J, Malhotra A, Hirsch C, Capasso J, Schaible TF (1982) Physiologic cardiac hypertrophy corrects contractile protein abnormalities associated with pathologic hypertrophy in rats. J Clin Invest 70: 1300–1305PubMedCrossRefGoogle Scholar
  36. 36.
    Swain JL, Sabina RL, Peyton RB et al. (1982) Derangements in myocardial purine and pyrimidine nucleotide metabolism in patients with coronary artery disease and left ventricular hypertrophy. Proc Nat Acad Sci USA 79: 655–659PubMedCrossRefGoogle Scholar
  37. 37.
    Swynghedauw B (1986) Developmental and functional adaptation of contractile proteins in cardiac and skeletal muscles. Physiol Rev 66: 710–771PubMedGoogle Scholar
  38. 38.
    Tada M, Yamamoto T, Tonomura Y (1978) Molecular mechanisms of active calcium transport by sarcoplasmic reticulum. Physiol Rev 58: 1–79PubMedGoogle Scholar
  39. 39.
    Tusuchimochi H, Kuro-o M, Takaku F, Yoshida K, Kawana M, Kimata S-I, Yazaki Y (1986) Expression of myosin isozymes during the developmental stage and their redistribution induced by pressure overload. Jap Circ J 50: 1044–1052CrossRefGoogle Scholar
  40. 40.
    Wearn JT (1939–40) Morphological and functional alterations of the coronary circulation. Harvey Lect35:243–270, 1939–1940Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • Arnold M. Katz
    • 1
  1. 1.Cardiology Division, Department of MedicineUniversity of ConnecticutFarmingtonUSA

Personalised recommendations